Monday, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for ATTR amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a type of heart muscle disease that occurs when amyloid fibrils – clumps of misfolded proteins – are deposited into heart tissue and cause it to stiffen. Also Read: Analysts Express Confidence in Alnylam’s Hypertension Drug Despite Mixed Trial Data. The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular (CV) events during the double-blind period ...